Navigation Links
Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
Date:11/14/2013

THOUSAND OAKS, Calif., Nov. 14, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will host a webcast investor meeting at the American Heart Association (AHA) Scientific Sessions 2013 on Tuesday, Nov. 19, at 7 p.m. CST. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate at the investor meeting to discuss data being presented at AHA.

Live audio of the investor meeting will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. 

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. 

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Korea , Jan. 24, 2017 Mezzion ... in New Jersey State court alleging that Dr. Reddy,s ... in its Food and Drug Administration (FDA) cGMP practices, ... that Dr. Reddy,s repeatedly represented to Mezzion that it ... its misconduct from Mezzion.  The suit also states that ...
(Date:1/24/2017)... 2017 The global  active pharmaceutical ingredients (API) market ... based on a new report by Grand View Research, Inc. The rising ... the market over the forecast period. Advancements in recombinant molecular technologies and ... growth.  Continue Reading ... ...
(Date:1/24/2017)... January 24, 2017 Aptuit, LLC, ... Surgical Laboratory des Massachusetts General Hospital (MGH) unter Leitung ... es um die Identifizierung und Validierung neuartiger Targets in ... sie der Resistenz von Antibiotika bei der Behandlung schwerer ... ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... , ... Center for Hispanic Leadership (CHL) Academy , the talent development ... Employee & Labor Relations at City of Hope , a world-renowned independent research ... City of Hope is committed to stay out in front of its communities’ growing ...
(Date:1/24/2017)... Iowa City, IA (PRWEB) , ... January 24, 2017 , ... ... in the country, has taken great care to design a program that provides teachers ... language abroad and domestically. This online teaching certificate is ideal for post-baccalaureate students and ...
(Date:1/24/2017)... , ... January 24, 2017 , ... The NewKILO JRP, ... Institutes (NMIs) and co-funded by the European Union (EU), was completed in May 2015. ... vacuum, instead being maintained and used in air, which presents some challenges to establishing ...
(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... water, has officially unveiled its latest award-winning bottles, designed specifically to optimize the ... , Taza Agua is renowned for introducing the world’s first untouched bottled ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Speaking With God’s Voice”: a resolute ... the creation of published author, Louis A. Miraglia, a born-again believer, who spent his ... God’s great, impactful Word. , “There is little doubt that God Himself prepared ...
Breaking Medicine News(10 mins):